Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
November 5, 2026
ACR 2026 Preview: CAR-T, Emerging Immune Therapies and AI in Rheumatology
November 5, 2026
AHA Scientific Sessions 2026 Preview: Cardiovascular Outcomes, Emerging Therapies and AI
November 5, 2026
Cardiovascular Strategic Roundup: Device Innovation and Treatment Value | Oct 01 – Nov 04, 2026
November 4, 2026
Evestia Clinical Acquires Emtex Life Science | Lucid Diligence Brief
November 4, 2026
Neuroscience Strategic Roundup: Emerging Therapies and Competitive Shifts | Sep 29–Nov 3, 2026
November 3, 2026
SITC 2026 Preview: Emerging Cancer Immunotherapies and Industry Developments
November 3, 2026
Endocrinology Strategic Roundup: Access and Innovation | Sep 29 – Nov 2, 2026
October 30, 2026
BioMarin’s $475M Fabry Disease Licensing Deal | Lucid Diligence Brief
October 30, 2026
Public Health Strategic Roundup: Prevention and Early Detection | Sep 25 – Oct 29, 2026
October 27, 2026
Immunology Strategic Roundup: Rising Evidence Standards | Sep 22—Oct 26, 2026
October 26, 2026